Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments
Jaime Bosch, Roberto J. Groszmann, Vijay H. Shah · Journal of Hepatology · 2015
Among the common complication of cirrhosis portal hypertension witnessed a major improvement of prognosis during the past decades. Principally due to the introduction of rational treatments based on new pathophysiological paradigms (concepts of thought) developed in the 1980s. The best example being the use of non-selective beta-blockers and of vasopressin analogs, somatostatin, and its analogs. Further refinement in the knowledge of the molecular mechanisms involved in the regulation of both the splanchnic and hepatic circulation has led to the emergence of new treatments, which are based on evidence that show not only structural but also vasoactive components increase the hepatic vascular resistance, as well as of angiogenesis. This knowledge and future improvements will most likely result in more effective treatment of portal hypertension and effective prevention of its complications in early stages.
Cited by 252 works. doi:10.1016/j.jhep.2015.01.003
Authors
References
- Clinical Applications of Research on Angiogenesis
- TLR4 enhances TGF-β signaling and hepatic fibrosis
- THE CARDIAC OUTPUT AT REST IN LAENNEC'S CIRRHOSIS 1
- Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage
- Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis
- The burden of liver disease in Europe: A review of available epidemiological data
- PROPRANOLOL—A MEDICAL TREATMENT FOR PORTAL HYPERTENSION?
- Pathogenesis of Liver Fibrosis
- Management of Varices and Variceal Hemorrhage in Cirrhosis
- Hemodynamic Response to Pharmacological Treatment of Portal Hypertension and Long–Term Prognosis of Cirrhosis